Integumen PLC (LON:SKIN), the developer of Labskin technology, has signed multi-year agreements with two Top 10 global cosmetic companies for recurring LabskinAI services.

Labskin scientists cloned 16 swabs of skin from the cheeks of healthy volunteers into 54 Labskin test subjects to allow sequencing of microbial DNA for the identification and quantification of the bacterial microbiome isolated and pooled together. The live bacteria, virus and fungi (microbiota) was consistent on all 54 test subjects for up to 7 days in the Labskin laboratories in York, UK

Labskin is proud to announce that our sister company Rinocloud is a finalist in the IT@Cork #TechLeaders19 “One to Watch” category, featuring our Labskin AI technology.

This conference is an annual event that brings together industry leaders and academics to discuss opportunities in formulations and product development through presentations and networking sessions.

Our message at the CBD Expo, simplified, was “Labskin is the science for CBD product compliance!”. Labskin will offer CBD brands verifiable scientific data that backs up product claims without the cost of hiring a full-time microbiologist and major capital investment in a microbiology laboratory.

Rinocloud, a subsidiary of Integumen plc and sister company of Labskin, is proud to announce it has been shortlisted for an award from AI Awards Ireland.

On the 10th September 2019, the United States Environmental Protection Agency’s (EPA) Administrator Mr Andrew Wheeler signed a new directive to prioritise efforts to reduce and eliminate animal testing across the United States of America.